These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38344449)

  • 1. Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.
    Ye L; Schneider JS; Ben Khaled N; Schirmacher P; Seifert C; Frey L; He Y; Geier A; De Toni EN; Zhang C; Reiter FP
    Liver Cancer; 2024 Feb; 13(1):6-28. PubMed ID: 38344449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
    Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
    Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
    Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
    World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.
    Choi JH; Ro JY
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hepatocellular-cholangiocarcinoma: An update.
    Beaufrère A; Calderaro J; Paradis V
    J Hepatol; 2021 May; 74(5):1212-1224. PubMed ID: 33545267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Acylphosphatase 1 Expression in Combined HCC-iCCA, HCC, and iCCA.
    Sakano Y; Noda T; Kobayashi S; Kitagawa A; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Asaoka T; Tanemura M; Umeshita K; Mimori K; Doki Y; Eguchi H
    Dig Dis Sci; 2022 Aug; 67(8):3817-3830. PubMed ID: 34626299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma.
    Wang T; Wang W; Zhang J; Yang X; Shen S; Wang W
    Front Oncol; 2020; 10():598433. PubMed ID: 33363028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.
    Cutolo C; Dell'Aversana F; Fusco R; Grazzini G; Chiti G; Simonetti I; Bruno F; Palumbo P; Pierpaoli L; Valeri T; Izzo F; Giovagnoni A; Grassi R; Miele V; Barile A; Granata V
    Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
    Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
    JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 14. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
    Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
    J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Strategies for Combined Hepatocellular-Cholangiocarcinoma (cHCC-CC).
    Bahra M; Yahyazadeh A
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
    Gigante E; Hobeika C; Le Bail B; Paradis V; Tougeron D; Lequoy M; Bouattour M; Blanc JF; Ganne-Carrié N; Tran H; Hollande C; Allaire M; Amaddeo G; Regnault H; Vigneron P; Ronot M; Elkrief L; Verset G; Trepo E; Zaanan A; Ziol M; Ningarhari M; Calderaro J; Edeline J; Nault JC
    Liver Cancer; 2022 Sep; 11(5):460-473. PubMed ID: 36158591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.
    Chu KJ; Kawaguchi Y; Wang H; Jiang XQ; Hasegawa K
    J Clin Transl Hepatol; 2024 Feb; 12(2):210-217. PubMed ID: 38343605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG
    J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.